本文已被:浏览 163次 下载 159次
投稿时间:2026-05-15 网络发布日期:2026-10-23
投稿时间:2026-05-15 网络发布日期:2026-10-23
中文摘要: 脓毒症是一种由感染引发的危及生命的综合征,其发病机制涉及免疫失调与代谢重编程的复杂相互作用,其中脂质代谢紊乱发挥重要作用。近年来研究表明,脓毒症患者常表现为三酰甘油升高,胆固醇尤其是高密度脂蛋白(HDL)水平降低,这些变化不仅反映疾病严重程度,也与炎症调控和内毒素清除过程相关。基于此,靶向脂质代谢的治疗策略逐渐受到关注,包括他汀类、贝特类、前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型(PCSK9)抑制剂、胆固醇酯转运蛋白(CETP)抑制剂以及重组HDL 和载脂蛋白AⅠ模拟肽等。尽管部分药物在实验研究中显示出抗炎和改善预后的潜力,但临床研究结果有限。未来研究需关注脂蛋白功能、疾病分期及患者异质性,并结合多组学与精准医学方法,以推动脂质代谢靶向治疗的临床转化。
中文关键词: 脓毒症 脂质代谢 高密度脂蛋白 免疫代谢 胆固醇酯转运蛋白抑制剂
Abstract:Sepsis is a life-threatening syndrome caused by infection ,characterized by a complex interplay between immune dysregulation and metabolic reprogramming,in which lipid metabolism plays a critical role. Recent studies have shown that patients sepsis commonly exhibit elevated triglyceride levels and reduced cholesterol levels,particularly high-density lipoprotein(HDL).These changes not only reflect disease severity,but are also related to the regulation of inflammation and endotoxin clearance. Based on these findings,therapeutic strategies targeting lipid metabolism have gained increasing attention,including statins,fibrates,proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors,cholesteryl ester transfer protein(CETP)inhibitors,as well as reconstituted HDL and apolipoprotein A Ⅰmimetic peptides. Although some of these agents have demonstrated anti-inflammatory effects and potential prognostic benefits in experimental studies,clinical evidence remains limited. Future research should focus on lipoprotein functionality,disease stage ,and patient heterogeneity ,and integrate multi-omics and precision medicine approaches to facilitate the clinical translation of lipid-targeted therapies in sepsis.
keywords: Sepsis Lipid metabolism High-density lipoprotein Immunometabolism Cholesteryl ester transfer protein inhibitor
文章编号: 中图分类号:R631 R977 文献标志码:A
基金项目:江苏省中医药和中西医结合科研项目(CYTF2026048)
附件
| 作者 | 单位 |
| 孙诗钰 | 1. 中国人民解放军联勤保障部队第九○四医院药剂科,江苏 无锡 214000 |
| 徐俊伟 | 2. 南京医科大学附属脑科医院南京市胸科医院心血管内科,江苏 南京 210029 |
| 陆佳赟 | 1. 中国人民解放军联勤保障部队第九○四医院药剂科,江苏 无锡 214000 |
| 孙舒 | 1. 中国人民解放军联勤保障部队第九○四医院药剂科,江苏 无锡 214000 |
引用文本:
孙诗钰,徐俊伟,陆佳赟,等.脂质代谢调节药物治疗脓毒症的研究进展[J].中国临床研究,2026,39(10):1632-1636.
孙诗钰,徐俊伟,陆佳赟,等.脂质代谢调节药物治疗脓毒症的研究进展[J].中国临床研究,2026,39(10):1632-1636.
